血管免疫母细胞性T细胞淋巴瘤
医学
淋巴瘤
临床试验
耐火材料(行星科学)
肿瘤科
生物信息学
病理
免疫学
T细胞
生物
免疫系统
天体生物学
作者
Mahasen Saleh,Ahmed Kotb,Shimaa Abdallah Ahmed,Ibrahim N. Muhsen,Riad El Fakih,Mahmoud Aljurf
标识
DOI:10.3390/curroncol28060456
摘要
Angioimmunoblastic T cell lymphoma (AITL) is a common subtype of mature peripheral T cell lymphoma (PTCL). As per the 2016 World Health Organization classification, AITL is now considered as a subtype of nodal T cell lymphoma with follicular helper T cells. The diagnosis is challenging and requires a constellation of clinical, laboratory and histopathological findings. Significant progress in the molecular pathophysiology of AITL has been achieved in the past two decades. Characteristic genomic features have been recognized that could provide a potential platform for better diagnosis and future prognostic models. Frontline therapy for AITL was mainly depending on chemotherapy and the management of relapsed or refractory AITL is still unsatisfactory with a very poor prognosis. Upfront transplantation offers better survival. Novel agents have been introduced recently with promising outcomes. Several clinical trials of combinations using novel agents are underway. Herein, we briefly review recent advances in AITL diagnosis and the evolving treatment landscape.
科研通智能强力驱动
Strongly Powered by AbleSci AI